Document Detail


Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?
MedLine Citation:
PMID:  7891054     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of the present study was to determine the risk of major haemorrhagic complications, stroke and other cardiovascular events, and mortality during long-term anticoagulant therapy (ACT) in patients with cerebrovascular disease not included in any prospective trials. DESIGN: The data were collected retrospectively. SETTING: All patients with symptomatic cerebrovascular disease discharged from the Stroke Unit, Aker University Hospital, Oslo, with ACT (warfarin) during 1983 through to 1986 were included. SUBJECTS: The material consists of 161 patients with a mean age of 67.8 (range 40-90) years. The reason for initiating ACT was frequent transient ischaemic attacks (TIAs) in 52 patients, stroke in progression (SIP) in 33 patients, and probable embolic stroke in 76 patients. International normalized ratio (INR) of 4.2-2.8 was aimed at. MAIN OUTCOME MEASURES: Major haemorrhagic complications, recurrent stroke and survival was determined for the total material, and in the subgroups non-valvular atrial fibrillation (NVAF, n = 49), TIAs, and SIP. RESULTS: The mean duration of ACT was 21.1 (range 0.5-60.2) months with a total of 282.9 patient-years. The rate of major (including fatal) haemorrhagic complications was 4.6% per year, and the rate of fatal haemorrhagic complications was 1.4% per year. The complication rates in the subgroups of patients did not differ significantly from that in the total material. Only two out of the 13 major haemorrhagic complications occurred during the initial 6 months of ACT. No strokes occurred in the TIA subgroup. The rate of recurrent stroke (excluding intracranial haemorrhage) was 3.9% per year for all patients, 4.7% per year for the patients with NVAF, and 4.2% per year for the patients with SIP. CONCLUSIONS: The total results suggest a positive net effect of ACT in patients with NVAF and TIAs. Without comparable data, no definite conclusions concerning the effect of ACT on patients with SIP can be drawn. The rate of bleeding complications was similar to that in other studied materials and is not negligible. In patients with SIP and TIAs, ACT beyond 6 months should probably only be continued if aspirin is not tolerated or has proven ineffective in the particular patient.
Authors:
T Dahl; U Abildgaard; P M Sandset
Related Documents :
8091444 - Gait outcome in ambulatory hemiparetic patients after a 4-week comprehensive rehabilita...
17388994 - One-year outcome after first-ever stroke according to stroke subtype, severity, risk fa...
22840804 - Single-center experience in endovascular treatment for infrainguinal bypass obstructions.
23297394 - Weight-loss history as a predictor of obesity treatment outcome: prospective, long-term...
15175944 - Efficacy of interferon retreatment after relapse for chronic hepatitis c patients with ...
12508344 - A new three-layer-funnel-shaped esophagogastric anastomosis for surgical treatment of e...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of internal medicine     Volume:  237     ISSN:  0954-6820     ISO Abbreviation:  J. Intern. Med.     Publication Date:  1995 Mar 
Date Detail:
Created Date:  1995-04-19     Completed Date:  1995-04-19     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8904841     Medline TA:  J Intern Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  323-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Aker University Hospital, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anticoagulants / adverse effects*,  therapeutic use
Cerebral Hemorrhage / chemically induced*
Cerebrovascular Disorders / drug therapy*
Female
Humans
Male
Middle Aged
Recurrence
Retrospective Studies
Survival Analysis
Time Factors
Chemical
Reg. No./Substance:
0/Anticoagulants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Frequency of diabetes in family members of probands with non-insulin-dependent diabetes mellitus.
Next Document:  Predictors of mortality in hospitalized patients with secondary upper gastrointestinal haemorrhage.